In Situ Single Cell Proteomics Reveals Circulating Tumor Cell Heterogeneity during Treatment

ACS Nano ◽  
2021 ◽  
Author(s):  
K. Kamil Reza ◽  
Shuvashis Dey ◽  
Alain Wuethrich ◽  
Jing Wang ◽  
Andreas Behren ◽  
...  
2021 ◽  
Vol 5 (1) ◽  
Author(s):  
Vincenza Conteduca ◽  
Sheng-Yu Ku ◽  
Luisa Fernandez ◽  
Angel Dago-Rodriquez ◽  
Jerry Lee ◽  
...  

AbstractNeuroendocrine prostate cancer is an aggressive variant of prostate cancer that may arise de novo or develop from pre-existing prostate adenocarcinoma as a mechanism of treatment resistance. The combined loss of tumor suppressors RB1, TP53, and PTEN are frequent in NEPC but also present in a subset of prostate adenocarcinomas. Most clinical and preclinical studies support a trans-differentiation process, whereby NEPC arises clonally from a prostate adenocarcinoma precursor during the course of treatment resistance. Here we highlight a case of NEPC with significant intra-patient heterogeneity observed across metastases. We further demonstrate how single-cell genomic analysis of circulating tumor cells combined with a phenotypic evaluation of cellular diversity can be considered as a window into tumor heterogeneity in patients with advanced prostate cancer.


2021 ◽  
Vol 53 (10) ◽  
pp. 1403-1404
Author(s):  
Radhika Mathur ◽  
Joseph F. Costello

Cancer Cell ◽  
2011 ◽  
Vol 19 (2) ◽  
pp. 244-256 ◽  
Author(s):  
Joaquim Calbo ◽  
Erwin van Montfort ◽  
Natalie Proost ◽  
Ellen van Drunen ◽  
H. Berna Beverloo ◽  
...  

Cancer ◽  
1984 ◽  
Vol 53 (6) ◽  
pp. 1420-1425 ◽  
Author(s):  
Richard E. Wilson ◽  
Karen H. Antman ◽  
Gilbert Brodsky ◽  
Joel S. Greenberger

Sign in / Sign up

Export Citation Format

Share Document